Stammzelltransplantation

In der Hämato-Onkologie ist die Transplantation von hämatopoetischen Stammzellen für die betroffenen Patienten oft die letzte Chance, geheilt zu werden. Durch viele Fortschritte bei der Stammzell-Gewinnung, den Konditionierungsregimen und den supportiven Therapien konnten die Ergebnisse in den letzten Jahren entscheidend verbessert werden.

• Literatur

• 1 Gratwohl A, Pasquini MC, Aljurf M. et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol 2015; 2: e91-e100
• 2 Rood JJV, Leeuwen AV. Leukocyte grouping. A method and its application. J Clin Invest 1963; 42: 1382-1390
• 3 Neefjes J, Jongsma ML, Paul P. et al. Towards a Systems understanding of MHC dass I and MHC dass II antigen presentation. Nat Rev Immunol 2011; 11: 823-836
• 4 Juric MK, Ghimire S, Ogonek J. et al. Milestones of hematopoietic stem cell transplantation – from first human studies to current developments. Front Immunol 2016; 7: 470
• 5 Gratwohl A, Sureda A, Cornelissen J. et al. Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. Leukemia 2017; 31: 1752-1759
• 6 Solomon SR, Sizemore CA, Sanacore M. et al. Total body irradiation-based Myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 2015; 21: 1299-1307
• 7 Passweg JR, Baldomero H, Basak GW. et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transpl 2019;
• 8 Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 2016; 127: 62-70
• 9 Passweg JR, Baldomero H, Bader P. et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants annually. Bone Marrow Transplant 2016; 51: 786-792
• 10 Gratwohl A. The EBMT risk score. Bone Marrow Transplant 2012; 47: 749-756
• 11 Armand P, Kim HT, Logan BR. et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014; 123: 3664-3671
• 12 Weaver CH, Buckner CD, Longin K. et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-1984
• 13 Holtick U, Albrecht M, Chemnitz JM. et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014;
• 14 Anasetti C, Logan BR, Lee SJ. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496
• 15 Hemmati PG. Allogene Stammzelltransplantation. Best Practice Onkol 2018; 13: 128-135
• 16 Bornhauser M, Kienast J, Trenschel R. et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13: 1035-1044
• 17 Fasslrinner F, Schetelig J, Burchert A. et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Hematol 2018; 5: e161-e169
• 18 Koreth J, Schlenk R, Kopecky KJ. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349-2361
• 19 Hahn T, Mccarthy Jr PL, Hassebroek A. et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013; 31: 2437-2449
• 20 Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood 2016; 127: 2824-2832
• 21 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676